[1]Cannon CP, Khan I, Klimchak AC, et al. Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease[J]. Am Heart J, 2019, 216: 30-41. [2]Sakaguchi M, Ehara S, Hasegawa T, et al. Coronary plaque rupture with subsequent thrombosis typifies the culprit lesion of non-ST-segment-elevation myocardial infarction, not unstable angina: non-ST-segment-elevation acute coronary syndrome study[J]. Heart Vessels, 2017, 32: 241-251. [3]Chen L, Qin L, Liu X, et al. CTRP3 alleviates Ox-LDL-induced inflammatory response and endothelial dysfunction in mouse aortic endothelial cells by activating the PI3K/Akt/eNOS pathway[J]. Inflammation, 2019, 42: 1350-1359. [4]Kemp BA, Howell NL, Padia SH. Intrarenal ghrelin receptor inhibition ameliorates angiotensin II-dependent hypertension in rats[J]. Am J Physiol Renal Physiol, 2018, 315: F1058-F1066. [5]Bai J, Yang F, Dong L, et al. Ghrelin protects human lens epithelial cells against oxidative stress-induced damage[J]. Oxid Med Cell Longev, 2017, 2017:1910450. doi: 10.1155/2017/1910450. [6]Li P, Liu Y, Xiang Y, et al. Ghrelin protects human umbilical vein endothelial cells against advanced glycation endproducts-induced apoptosis via NO/cGMP signaling[J]. Int J Clin Exp Med, 2015, 8: 15269-15275. [7]Tokudome T, Otani K, Miyazato M, et al. Ghrelin and the heart[J]. Peptides, 2019, 111: 42-46. [8]Ai W, Wu M, Chen L, et al. Ghrelin ameliorates atherosclerosis by inhibiting endoplasmic reticulum stress[J]. Fundam Clin Pharmacol, 2017, 31: 147-154. [9]Lilleness BM, Frishman WH. Ghrelin and the cardiovascular system[J]. Cardiol Rev, 2016, 24: 288-297. [10]Wang J, Zhao P, Gao Y, et al. The effects of anti-IL-23p19 therapy on atherosclerosis development in ApoE-/- mice[J]. J Interferon Cytokine Res, 2019, 39: 564-571. [11]Gliozzi M, Scicchitano M, Bosco F, et al. Modulation of nitric oxide synthases by oxidized LDLs: role in vascular inflammation and atherosclerosis development[J]. Int J Mol Sci, 2019, 20: 1-16. doi: 10.3390/ijms20133294. [12]Förstermann U, Xia N, Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclero-sis[J]. Circ Res, 2017, 120: 713-735. [13]Roth L, Van der Donckt C, Emini Veseli B, et al. Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability and reduces myocardial infarction in mice[J]. Vascul Pharmacol, 2019, 118-119:106561. doi: 10.1016/j.vph.2019.05.001. [14]Bai Y, Liu R, Li Z, Zhang Y, et al. VEGFR endocytosis regulates the angiogenesis in a mouse model of hindlimb ischemia[J]. J Thorac Dis, 2019, 11: 1849-1859. |